ImmunityBio and NantKwest
Broad Clinical-Stage Immunotherapy Platforms
NK & T Cell
We established ImmunityBio to advance the next generation of immunotherapies and to address serious unmet needs within oncology and infectious diseases. Our platform is designed to overcome limitations of the existing therapeutic paradigm based on T cell-based immunotherapies, such as checkpoint inhibitors and chimeric antigen receptor T cells, or CAR-T cells.
Fundamentally, our platform promotes innate and adaptive immune responses by activating cytokines, natural killer, or NK, cells, T cells and tumoricidal macrophages, and seeks to establish “immunological memory” to support longer-term protection against disease. We believe our novel approach significantly improves upon standard immunotherapies to induce more rapid, robust and durable clinical benefit.
Our Clinical Stage Platforms
(1) Antibody fusion proteins which activate NK, T, and memory T cells;
(2) Albumin-based tumor microenvironment immune modulators; and
(3) Second generation adenovirus (hAd5) and yeast vectors to activate dendritic cells and induce long-term T cell memory.
fast track &
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” The Pending Merger with ImmunityBio
The NantKwest Special Committee and the NantKwest Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 8, 2021 at 9:30...
CULVER CITY, Calif., February 24, 2021 — ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and...
ImmunityBio Announces ASCO Genitourinary Cancer symposium presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate
ImmunityBio Announces ASCO Genitourinary Cancer symposium presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate QUILT 3.032...